Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial (Q41185712)
Jump to navigation
Jump to search
scientific article published on 3 June 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial |
scientific article published on 3 June 2015 |
Statements
1 reference
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial (English)
1 reference
A Mehta
1 reference
K Papp
1 reference
D Thaçi
1 reference
K Reich
1 reference
E Riedl
1 reference
R G Langley
1 reference
J G Krueger
1 reference
A B Gottlieb
1 reference
H Nakagawa
1 reference
E P Bowman
1 reference
Q Li
1 reference
Y Zhou
1 reference
R Shames
1 reference
3 June 2015
1 reference
1 reference
173
1 reference
4
1 reference
930-939
1 reference
Identifiers
1 reference
1 reference